Medical (M)
713 patents · All patents
- US114198231 case →8/8 sections
As a senior US patent analyst, I have reviewed the provided documentation for US patent 11,419,823. While I cannot perform a live search of the USPTO database or CAFC dockets, the provided patent text contains the necessary information…
View full analysis →added 4/27/2026
- US115898801 case →8/8 sections
A concise summary of U.S. Patent No. 11,589,880, including a plain-language overview of its independent claims, is provided below. The patent is the subject of a lawsuit filed by AngioDynamics, Inc. against Endovascular Engineering, Inc…
View full analysis →added 4/27/2026
- US121616281 case →8/8 sections
Summary of U.S. Patent No. 12,161,628 Title: Combination therapy Assignee: Astellas Pharma Inc., Medivation Prostate Therapeutics LLC Inventors: Jacqueline GIBBONS, Joyce MORDENTI, Michiel DE VRIES, Walter KRAUWINKEL, Taoufik Ouatas Filing…
View full analysis →added 4/27/2026
- US124471281 case →8/8 sections
US Patent 12447128B2, titled "Formulations of enzalutamide," was issued on October 21, 2025, from an application filed on November 11, 2022. The patent is currently assigned to Astellas Pharma Inc and Medivation Prostate Therapeutics LLC…
View full analysis →added 4/27/2026
- US124960771 case →8/8 sections
An analysis of U.S. Patent 12,496,077 has been conducted based on the provided documentation. Summary of U.S. Patent 12,496,077 Title: Systems and methods for removing undesirable material within a circulatory system Assignee…
View full analysis →added 4/27/2026
- US125023571 case →8/8 sections
As a senior US patent analyst, I have reviewed the provided information for US patent 12502357. Below is a concise summary based on the authoritative patent text. Summary of US Patent 12502357 Title: Formulations of enzalutamide Assignee…
View full analysis →added 4/27/2026
An analysis of U.S. Patent 9,549,918 reveals a focus on improving the stability of the immunosuppressant drug tacrolimus in pharmaceutical formulations. As of the current date, there is no indication of active litigation involving this…
View full analysis →added 4/27/2026
- US116239201 case →7/8 sections
Patent Analyst Report: US 11,623,920 B2 Date of Analysis: 2026-05-05 Subject: United States Patent 11,623,920 B2 This report provides a concise summary of US patent 11,623,920, including its key bibliographic data and a plain-language…
View full analysis →added 4/27/2026
- US118396891 case →7/8 sections
A technical analysis of U.S. Patent 11,839,689 reveals it pertains to specific formulations of the prostate cancer drug enzalutamide, designed to improve its solubility and absorption. The patent is currently active and has been asserted…
View full analysis →added 4/27/2026
Summary of U.S. Patent No. 8,685,998 A concise summary of U.S. Patent No. 8,685,998 is provided below, based on a review of the United States Patent and Trademark Office (USPTO) database. A search of the 2026 dockets for the Court of…
View full analysis →added 4/27/2026
- US101661901 case →6/8 sections
US patent 10166190, titled "Stabilized tacrolimus composition," was issued to Veloxis Pharmaceuticals Inc. on January 1, 2019. The application for this patent was filed on January 13, 2017. The inventors are Nikolaj Skak and Per Holm…
View full analysis →added 4/27/2026
- US108641991 case →6/8 sections
Here is a concise summary of US Patent 10864199, including information from the USPTO and CAFC dockets. US Patent 10864199 Summary Title: Tacrolimus for improved treatment of transplant patients Current Assignee: Veloxis Pharmaceuticals…
View full analysis →added 4/27/2026
- US111100811 case →6/8 sections
US Patent 11110081: Summary and Claim Analysis Title: Tacrolimus for improved treatment of transplant patients Assignee: Veloxis Pharmaceuticals Inc. Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling Filing Date…
View full analysis →added 4/27/2026
- US111233311 case →6/8 sections
A concise summary of US Patent 11,123,331 is as follows: Title: Tacrolimus for improved treatment of transplant patients Assignee: Veloxis Pharmaceuticals, Inc. Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling…
View full analysis →added 4/27/2026
- US120831031 case →6/8 sections
Patent Summary: US 12,083,103 B2 Title: Tacrolimus for improved treatment of transplant patients Assignee: Veloxis Pharmaceuticals Inc. Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling Filing Date: August 4, 2021…
View full analysis →added 4/27/2026
- US124030951 case →6/8 sections
Analysis of U.S. Patent 12,403,095: Stabilized Tacrolimus Composition Date of Analysis: May 1, 2026 A detailed review of U.S. Patent 12,403,095 has been conducted. This document, titled "Stabilized tacrolimus composition," was issued on…
View full analysis →added 4/27/2026
- US125277711 case →6/8 sections
US patent 12527771, titled "Viral inhibitors, the synthesis thereof, and intermediates thereto," was assigned to Takeda Pharmaceutical Co Ltd. The inventors listed are Jeffrey Scott DEPUE, Suresh Kumar Tipparaju, Helge Alfred REISCH…
View full analysis →added 4/27/2026
Analysis of U.S. Patent 8,613,717 Date of Analysis: April 26, 2026 This report provides a summary of United States Patent 8,613,717, including its key bibliographic details and a plain-language explanation of its independent claims. ---…
View full analysis →added 4/27/2026
Patent Summary: US 8,664,239 B2 Title: Tacrolimus for improved treatment of transplant patients Assignee: Veloxis Pharmaceuticals Inc. Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling Filing Date: June 23, 2011…
View full analysis →added 4/27/2026
- US106394040 cases8/8 sections
I will now provide a concise summary of US patent 10639404 and search for its litigation status. US Patent 10639404 Summary Title: Wound dressing Assignee: WOUND HEALING TECHNOLOGIES LLC Inventor(s): Isaac Lichtenstein Filing Date: June 3…
View full analysis →added 5/14/2026